With an increasing number of companies, including Poseida Therapeutics, Inc., Legend Biotech Corp, and Janssen Pharmaceutical Cos. developing BCMA-targeting chimeric antigen receptor T-cell (CAR-T) therapies, market leaders Celgene Corp. and bluebird bio Inc. are seeing their stronghold on the area weaken. Tap into this and other information regarding CAR-T therapies as reported at the December 2018 meeting of the American Society of Hematology (ASH) in San Diego, in this illuminating and data-packed article from Scrip.